ODAIA is a technology company.
ODAIA delivers AI-powered commercial intelligence for life sciences, unifying data, accelerating results, and helping commercial teams deepen engagement and enhance care for providers and patients.
ODAIA has raised $43.0M across 4 funding rounds.
ODAIA has raised $43.0M in total across 4 funding rounds.
ODAIA is a Toronto-based technology company specializing in an AI-powered Customer Data Platform (CDP) designed for pharmaceutical and life sciences companies. It integrates proprietary and public data to analyze patient journeys, predict physician prescribing behavior (e.g., NBRX and TRX with 96% accuracy), and enable omnichannel attribution, delivering real-time insights for sales and marketing teams to create hyper-personalized engagements with healthcare providers (HCPs).[1][4][5] The platform, including products like ODAIA Field and ODAIA Field Coach, powers targeting, pre-call insights via GenAI, customer segmentation, and predictive actions integrated with CRM and marketing tools, helping biopharmas optimize commercial strategies beyond traditional reach-and-frequency metrics.[3][4][5] ODAIA demonstrates strong growth momentum as a UTEST graduate, seed-funded startup ($1.6M co-led by Panache and StandUp Ventures), trusted by innovative biopharmas, and certified as a Great Place to Work.[3][4]
ODAIA emerged from data analytics research at the University of Toronto's Faculty of Information and Faculty of Computer Science, with the startup formed to commercialize AI-driven customer journey intelligence technology.[3] Founded in 2018, the name derives from the Ancient Greek word for a salesperson's "tools of the trade," reflecting its mission to empower life sciences teams.[6] Key leaders include serial entrepreneur executives from Silicon Valley (e.g., semiconductor, IoT, SaaS, digital health with exits like Morega to AT&T), IT veterans from Ceridian and Capital One, and life sciences experts from IQVIA, Deloitte, Veeva Systems, and IMS Health/IQVIA, bringing decades of experience in analytics, commercial growth, and customer science across 100+ companies in 36 countries.[6] Early traction included UTEST acceleration, two patent applications in prosecution, and $1.6M seed funding, marking pivotal commercialization steps.[1][3]
(Older reference to MAPTUAL platform suggests platform evolution, now centered on ODAIA Field suite.[7])
ODAIA rides the wave of AI-driven precision medicine and commercial optimization in life sciences, where disparate data silos (CRM, ERP, support) hinder insights amid rising demands for personalized HCP engagement and patient outcomes.[3][6] Timing is ideal with exploding pharma data volumes, regulatory pushes for real-world evidence, and post-pandemic shifts to omnichannel strategies, amplified by GenAI advancements for explainable predictions.[4][5] Market forces like biopharma consolidation, competitive prescribing battles, and the need to predict dynamic behaviors favor ODAIA's edge over labor-intensive consulting or legacy tools.[3][5] It influences the ecosystem by empowering sales/marketing with actionable intelligence—trusted by top biopharmas—reducing manual bias, accelerating decisions, and ultimately enhancing health journeys through better provider interactions.[1][4]
ODAIA is poised for expansion by deepening AI integrations (e.g., advanced GenAI for competitor benchmarking) and targeting more biopharmas amid surging demand for predictive commercial tools. Trends like multimodal data fusion, regulatory AI adoption, and value-based care will propel its growth, potentially through Series A funding or partnerships with giants like IQVIA/Veeva. Its influence may evolve from niche pharma innovator to ecosystem standard-setter, scaling patented tech globally while maintaining explainability to build trust. This positions ODAIA as a transformative force, turning vast data into tools that directly improve patient access via smarter engagements—echoing its ancient namesake of empowering the trade.[3][4][6]
ODAIA has raised $43.0M in total across 4 funding rounds.
ODAIA's investors include BDC Venture Capital, Curie.Bio, First Round Capital, Flint Capital, Innospark Ventures, i/o Ventures, Meridian Street Capital, Niu Ventures, Operator Partners, Refactor Capital, SV Angel, Threshold Ventures.
ODAIA has raised $43.0M across 4 funding rounds. Most recently, it raised $25.0M Series B in April 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2023 | $25.0M Series B | BDC Venture Capital, Curie.Bio, First Round Capital, Flint Capital, Innospark Ventures, i/o Ventures, Meridian Street Capital, Niu Ventures, Operator Partners, Refactor Capital, SV Angel, Threshold Ventures, Transformation Capital, Venture Catalysts | India's First Integrated Incubator, Aaron Patzer, Amar Varma, Michelle McBane, Vivek Garipalli | |
| Feb 1, 2022 | $14.0M Series A | BDC Venture Capital, Collaborative Seed & Growth Partners, Flint Capital, Innospark Ventures, LearnLaunch Accelerator, LightShed Ventures, Speedy Packets Inc., Threshold Ventures, Trajectory Ventures, Amar Varma, Dave Balter, Michelle McBane | |
| Oct 1, 2020 | $3.0M Seed | BDC Venture Capital, Two Small Fish Ventures | |
| Sep 1, 2019 | $1.0M Seed | Camber Creek, Hyde Park Venture Partners, Storm Ventures, Joseph Fung, Michelle McBane |